Respiratory Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Streptococcus pneumonae characteristics:

A

Gram + cocci

lancet shapped diplococci

Alpha hemolytic on blood agar

Catalase negative

colonizes upper respiratory tract, important cause of infection in normally sterile parts of tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Streptococcus pneumonae immunity:

A

Antibody requires days to develop

90 different CPS that prevent phagocytosis (antigenic variation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Streptococcus pneumonae Epidemiology:

A

Mucosal surface of nasopharynx, humans are the only host

most common in non-immune hosts (infants and elderly)

also common when there is impaired antibody production or defective clearance of opsonized bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Diseases caused by Streptococcus pneumonae

A

-lobar pneumoina: most common community acquired pneumococcal pneumonia

shows patchy alveoli filled with acute inflammatory cells (structure in tact so usually clears with no damage)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Treatment of Streptococcus pneumonae:

A

altered penicillin binding proteins reduced affinity for penicillin

PBP confers resistance to most beta lactams

natural transformability exchanges these altered genes

resistant to most beta lactams - but can still be useful if concentration used is above organisms MIC (minimum inhibitory concentration)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hemophilus influenzae characteristics:

A
  • gram negative coccobacillus
  • colonized upper respiratory tract
  • requires two growth factors found in blood: hematin and NAD+
  • 6 types of capsules, B most virulent
  • resides in human nasopharynx
  • encapsulated strains cause invasive infection
  • nontypeable strains are unencapsulated, cause only upper respiratory tract infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hemophilus influenzae epidemiology:

A
  • nontypeable is leading cause of acute otitis media and conjuctivitis in children
  • COPD: chronic bronchitis in adults
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Middle ear infections:

A
  • common in children
  • fluid in middle ear space
  • becomes infected with organisms in the upper respiratory tract
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hemophilus influenzae type B:

A
  • most virulent
  • immunity based on antibody to CPS
  • controlled by immunization to type B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hemophilus influenzae treatment:

A
  • most are still sensitive to penicillin

- when resistant it is due to expression of beta lactamase so cephalosporins still effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Neisseria meningitidis characteristics:

A
  • gram negative bean shaped diplococcus
  • identical staining to neisseria gonorrhoeae
  • ultrastructural level has a prominent antiphagocytic polusaccharide capsule
  • 12 serogroups (A, B, C, Y and W-135 predominant)
  • antigenic varriation
  • DOES NOT CAUSE PNEUMONIA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Neisseria meningitidis epidemiology:

A
  • nasopharynx
  • older children, young adults (dorms, barracks)
  • resides in the upper respiratory tract but DOES NOT CAUSE DISEASE THERE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Neisseria meningitidis treatment:

A
  • penicillan
  • third generation cephalosporin
  • vaccine (none to serogroup B)
  • antibiotic prophylaxis in outbreaks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical diseases by Neisseria meningitidis:

A
  • two presentations:
    1) meningococcemia: skin lesions (petechiae and purpura), sepsis fulminant disease
    2) acute bacterial meningitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bordetella pertussis characteristics:

A
  • gram negative coccobacillus of upper respiratory tract
  • whooping cough
  • ciliated surfaces of the upper respiratory tract
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bordetella pertussis toxin:

A
  • sense environmental signals such as temp which causes changes in gene regulation
  • ADP ribosylates adenylate cyclase G regulatory protein which prevents inhibition of adenylate cyclase (increases cAMP)
  • increased cAMP promotes respiratory secretions and reduces phagocytic activity
  • toxin causes marked lymphocytosis (high lymphocytes) which is a hallmark of the disease
  • toxin-mediated damage to the respiratory epithelium results in prolonged illness characterized by PAROXYSMAL COUGH
17
Q

Bordetella pertussis stages of disease:

A

1) catarrhal stage: same as viral upper respiratory tract infection
2) paroxysmal stage: coughing, may not have whoop
3) convalescent stage: 100 day cough, complications in infants who may acquire pneumonia or apnea

18
Q

Bordetella pertussis epidemiology:

A
  • high mortality in infants, spread by adults

- HIGHLY contagious

19
Q

Bordetella pertussis prevention:

A
  • diagnosis by fluorescent antibody testing or culture swab with non-routine medium (Bordet-Gengou)
  • treat with erythromycin or macrocodes
  • treat close contact
  • Immunization: acellular vaccine (DTaP), boosters for adults
20
Q

mycoplasma pneumoniae:

A
  • extracellular pathogen
  • mollicutes class: NO CELL WALL, does not take up gram stain
  • not killed by penicillins or beta lactam antibiotics
  • “atypical” pneumonia
  • test with serology or PCR, not routinely grown in labs
  • intersitial infiltrates on multiple lobes

“WALKING PNEUMONIA”

21
Q

Pseudomonas aeruginosa:

A
  • ubiquitous, opportunistic pathogen
  • gram negative rod
  • aerobic
  • minimal growth requirements, lives in many environments
  • easy to grow in lab: oxidase positive, non-lactose fermenting, pigmented and smells sweet (smell of the locker room is this bacteria)
22
Q

Pseudomonas aeruginosa epidemiology:

A
  • thrives in warm, moist, air, damage
  • environmental, not host
  • many hospital sinks, basins, toilets, etc
23
Q

Pseudomonas aeruginosa pathogenesis:

A
  • limits neutrophil mediated clearance by contact dependent injection of toxins
  • airways on CF patients become chronically infected
24
Q

Pseudomonas aeruginosa diseases:

A
  • Pulmonary: nosocomial pneumonia, chronic CF infections
  • Skin: hot tub folliculitis, infections of burns
  • otitis externea: swimmer’s eart
  • corneal infections
  • bacteremia: vascular catheter infections, neutropenic patients
25
Q

biofilms:

A

bacteria growing on a surface

  • dynamic microbial community encased in an extracellular matrix
  • frequent mode of growth for pseudomonas
  • enhanced resistance to antibiotics
26
Q

Pseudomonas aeruginosa treatment:

A
  • antibiotic resistance is major problem
  • produce beta lactamases, mutations in porins reduce uptake, exchange of plasmids encoding resistance, reduced susceptibility of biofilms
  • use anti-pseudomonal penicillins or 4th generation cephalosporins
  • combinations for synergistic (IE) anti-pseudomonal penicillin and aminoglycoside
  • no vaccine
27
Q

Other difficult to treat gram negative rods:

A
  • opportunistic respiratory
  • burkholderia cepacia
  • stenotrophomonas maltophilia
  • acinetobacter species
  • KPS: klebsiella pneumoniae produces extended sprectrum beta lactase
28
Q

Legionela pneumophila:

A
  • accidental human pathogen
  • causes legionaires diseases
  • gram negative motile coccobacilli
  • non-fermentative
  • poor gram stain
  • parasite of aquatic protozoa (amoebae)
  • falsely recognizes macrophages in human as natural host (survives in macrophage vacuole)
29
Q

Legionela pneumophila epidemiology:

A
  • water system outbreaks
  • more common in elderly
  • correlation with heavy tobacco/alcohol use
  • men more likely to get infected
  • no person to person spread
30
Q

Legionela pneumophila diseases:

A
  • infections

- pneumonia and extra-pulmonary complications

31
Q

Legionela pneumophila treatment:

A

-macrolides or fluoroquinolones